Explore compound identities, study findings and source-linked explanations of peptide research.
Semaglutide has randomized human evidence for weight management and, in a defined population, cardiovascular risk reduction. Route, formulation, indication and trial population remain essential to interpreting those results.
Tirzepatide is a dual GIP/GLP-1 receptor agonist with large randomized human trials. Evidence for specified prescription products should not be transferred to unverified vials or self-directed treatment schedules.
Retatrutide targets GIP, GLP-1 and glucagon receptors. Randomized human studies show substantial weight reductions, but trial results do not establish the identity, safety or efficacy of online research products.
Cagrilintide is a long-acting amylin analogue studied alone and with semaglutide. Human trial findings are substantial, but combination results cannot be assigned to cagrilintide alone or to an unverified blend.
AOD-9604 has animal experiments and human development history. The key distinction is that promising mouse findings did not establish clinically useful weight loss in the larger oral human trial reviewed by FDA.
KLOW is a marketed blend name, not a single peptide or a demonstrated weight-loss treatment. Start with the ingredient list and the exact molecules before drawing conclusions from research.
Human BPC-157 reports exist, but the studies examined here are small and uncontrolled. They do not establish reliable clinical benefit, long-term safety or equivalence between formulations and routes.
TB-500 is not a sufficiently precise identity on its own. A primary analytical paper identified acetylated LKKTETQ in one product; that does not make every TB-500 product equivalent to full-length thymosin beta-4.
A small uncontrolled human report included BPC-157 with thymosin beta-4, but it does not establish that an unspecified BPC/TB-500 product is effective, safe or synergistic.
LL-37 has human topical wound studies, including a larger trial without significant overall healing benefit. Its normal biological role does not establish that external administration is uniformly beneficial or safe.
The selected MOTS-c papers describe cells, mouse interventions and endogenous human measurements. They do not establish the efficacy of administered native MOTS-c in people; CB4211 is a separately named investigational intervention.
Foundational GHK-Cu papers include fibroblast culture and rat wound experiments. They support specific research observations, not blanket claims of human rejuvenation or systemic treatment benefit.
Epithalon has laboratory telomerase findings. Human reports using Epithalamin are not automatically trials of this defined tetrapeptide, and telomere changes do not establish longer or healthier human life.
SNAP-8 is acetyl octapeptide-3. Human research includes a multi-ingredient dissolving-microneedle patch, but that is not proof of isolated SNAP-8 efficacy or systemic injection safety.
GLOW is a marketed blend of GHK-Cu, BPC-157 and TB-500. Its component studies address different materials and models; they do not add up to a demonstrated clinical benefit from the finished three-component product.
NAD+ is a coenzyme, not a peptide. Small human infusion studies describe metabolite handling and tolerability; they do not establish general rejuvenation, disease treatment or long-term safety.
Human studies of long-acting CJC-1295 measured growth-hormone and IGF-I responses. They do not establish equivalent exposure for no-DAC products or demonstrate general anti-aging, muscle-building or fat-loss benefits.
Ipamorelin can stimulate GH under studied conditions. Human pharmacology and postoperative research do not establish a general anti-aging, sleep, muscle or fat-loss treatment, and preclinical selectivity is not a human safety guarantee.
Different endocrine pathways can motivate combination research, but they do not prove a CJC/ipamorelin blend is superior or safe. The first question is whether the CJC component is the albumin-binding study molecule or a separately identified no-DAC material.
Sermorelin has a specific pediatric and diagnostic history. The selected child-growth study and FDA's Geref record do not validate general adult rejuvenation claims or make every compounded or research formulation equivalent to the historical medicine.
Tesamorelin has randomized clinical evidence and a specific approved-product context for excess abdominal fat in adults with HIV-associated lipodystrophy. That is not a general weight-loss indication.
Tesamorelin's HIV-associated visceral-fat research and ipamorelin's hormone and postoperative studies answer different clinical questions. Combining their names does not combine their evidence or establish an additional benefit.
PT-141 is bremelanotide, a melanocortin receptor agonist. Clinical evidence and the Vyleesi approval concern a defined formulation and population—not a general sexual-performance claim or every product sold under the molecule's name.
Kisspeptin-10 can affect LH secretion under studied conditions, but responses differ by physiological context. Small hormone experiments are not proof of improved fertility, lasting testosterone benefit or a broadly safe personal regimen.
SLU-PP-332 is an experimental small molecule, not a peptide. Its published preclinical findings do not establish a human exercise replacement, weight-loss regimen or safe personal dose.
Selank has published human research. Small active-comparator and imaging studies need to be read on their own terms, not converted into guaranteed anxiety relief, cognitive enhancement or a personal regimen.
Semax has human and animal research, but brain imaging, rehabilitation outcomes and rodent neurotrophin measurements answer different questions. None justifies a universal cognitive-enhancement promise.
DSIP has small human sleep experiments, not a uniformly positive clinical record. A controlled insomnia study found weak effects and no change in subjective sleep quality.
L-carnitine has human research and prescription uses, but neither supports treating every carnitine product as an established fat-loss intervention. The clearest reading separates the molecule, formulation, route, population and outcome.
LIPO-C is a formulation name, not a single peptide. The Heritage listing describes a methionine–inositol–choline solution; biochemical roles of those ingredients do not by themselves establish a weight-loss benefit from the mixture.
Bacteriostatic water is a preserved diluent, not a universal peptide formulation. The exact product label, compatible material, container and intended use determine what can be concluded about a preparation.
A clear solution is not proof of a stable or injectable preparation. Acetic acid can be part of a particular laboratory formulation, but solvent choice and storage conditions must be validated for the exact material.